Aleix Prat

36.2k citations
395 papers · 14.7k indexed · 6 hit papers · h-index 55

Aleix Prat

367 papers receiving 14.5k citations

Hit Papers

Alpelisib plus fulvestran...223201020262015202050010001.5k

Peers

Aleix Prat
Comparison fields: 5 of 142
  • Cancer Research 6.1k
  • Oncology 8.9k
  • Pulmonary and Respiratory Medicine 3.5k
  • Molecular Biology 5.8k
  • Pathology and Forensic Medicine 1.1k
Replace Melinda E. Sanders with:
Melinda E. Sanders United States
Lyndsay N. Harris United States
Ronald Simon Germany
Timothy A. Yap United States
Angelo Di Leo Italy
François Bertucci France
Nicola Normanno Italy
Aňa Lluch Spain
Tomofumi Osako Japan
Ingrid A. Mayer United States
Aleix Prat relative to Melinda E. Sanders United States Melinda E. Sanders's profile →
Citations per field
00.5×1.6×
Melinda E. Sanders · 1×
Citations per year

Countries citing papers authored by Aleix Prat

Since Specialization
Citations

This map shows the geographic impact of Aleix Prat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aleix Prat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aleix Prat more than expected).

Fields of papers citing papers by Aleix Prat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aleix Prat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aleix Prat. The network helps show where Aleix Prat may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Aleix Prat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Aleix Prat Line = papers co-authored together Aleix Prat links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20247
2 20244
3 20231
4 20230
5 202328
6 20231
7 20231
8 20217
9 202111
10 202126
11 202038
12 202062
13 20190
14 2017277
15 2016106
16 201564
17 2015147
18 201433
19 201340
20 2011160

About Aleix Prat

Aleix Prat is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine, having authored 395 papers that have together received 14.7k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (157 papers), HER2/EGFR in Cancer Research (157 papers), Breast Cancer Treatment Studies (152 papers), Cancer Treatment and Pharmacology (71 papers), Cancer Immunotherapy and Biomarkers (52 papers), Cancer Genomics and Diagnostics (44 papers), Monoclonal and Polyclonal Antibodies Research (33 papers) and Cancer Cells and Metastasis (25 papers). The work is most often cited by research in Cancer Research (6.1k citations), Oncology (8.9k citations) and Pulmonary and Respiratory Medicine (3.5k citations). Aleix Prat has collaborated with scholars based in Spain, United States and Italy. Frequent co-authors include Charles M. Perou, Joel S. Parker, Cheng Fan, Bárbara Adamo, Xiaping He, Olga Karginova, Chad Livasy, Jason I. Herschkowitz, Patricia Galván and Lisa A. Carey. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, ESMO Open and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026